Meredith Buxton, PhD, MPH

Chief Executive Officer / President

Dr. Meredith Buxton was named Chief Executive Officer of GCAR in March 2020. She previously served as the organization’s Chief Operating Officer since 2019.

Involved in clinical research and drug development for over 20 years, Dr. Buxton has been instrumental in the establishment of several innovative clinical research programs, with extensive experience in building and running master protocols and adaptive platform trials.

Dr. Buxton brings expertise in scientific and operational implementation, regulatory strategy, partnership development, and consortium building with a focus on improved and efficient approaches to the design and execution of clinical trials.

Before joining GCAR, Dr. Buxton co-founded the Clinical Trial Strategy Group at Berry Consultants, serving as Director of Clinical Trial Strategy, and provided strategic guidance and implementation expertise for several master protocols by pharma and nonprofit sponsors. 

Previously, Dr. Buxton was Assistant Professor at the University of California, San Francisco, where she was Executive Director of the I-SPY Program including the I-SPY 2 TRIAL, a phase 2 response adaptive randomization platform trial considered a seminal adaptive platform trial in oncology.

Dr. Buxton earned an undergraduate degree at Stanford University and completed a Master’s in Public Health and PhD in Epidemiology from Columbia University.